Akademik Veri Yönetim Sistemi
KAFKAS UNIVERSITESI VETERINER FAKULTESI DERGISI, cilt.27, sa.1, ss.51-56, 2021 (SCI-Expanded)
Leishmaniasis is recognized as a neglected disease by the World Health Organization (WHO). New treatment modalities are needed for the treatment of leishmaniasis due to the limited number of drugs that can cause toxic side effects. Therefore, studies are being carried out on herbal extracts, which can be potential candidates for the treatment. Pelargonium sidoides a perennial herb originating in Africa, is used to treat infectious diseases.The aim of this study was to perform in vitro investigation of the direct effect of P. sidoides commercially available root extract (EPs 7630) on promastigotes of Leishmania infantum and Leishmania tropica. For this purpose, L. infantum and L. tropica strains were grown on NNN medium and then transferred into RPMI 1640 medium supported by 10% fetal bovine serum. After mass growing, the promastigotes were placed into 96-well plates with L. infantum as 5x10(4) and L tropica as 1.5x10(5). EPs 7630 was diluted at a concentration of 400, 200, 100 and 50 mu g/mL. Afterwards, EPs 7630 was added and then counted by hemocytometry at 24, 48, 72, and 96 h. The calculations were done after the experiments repeated three times. Comparison with the control group and liposomal am photericin B showed that EPs 7630 had no inhibitory effect on the growth of Leishmania promastigotes at the concentrations of 50 and 100 mu g/mL, a partial inhibitory effect at 200 mu g/mL, and an inhibitory effect at 400 g/mL. It was concluded that identifying the substance(s) responsible for the antileishmanial effect of P. sidoides extract, conducting toxicity studies, and improving the results of these studies in in vivo models may be useful as steps for future clinical studies.